{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-117144","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.109931+00:00","generated_at":"2026-05-16T15:51:39.410351+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Altimmune CEO Vipin Garg to step down Jan 1, 2026; Chairman Jerome Durso named successor","bullets":["Vipin Garg transitions from President/CEO to advisor through June 30, 2026; remains on board until Jan 31, 2026.","Jerome Durso, current Chairman and former Intercept CEO, becomes President and CEO effective Jan 1, 2026.","Durso receives annual base salary of $725,000, target bonus 60% of base, and equity grants of 633,700 RSUs and 1,824,400 stock options.","Garg will receive severance: 12 months base salary, COBRA subsidy, continued equity vesting through separation date.","Altimmune expects End-of-Phase 2 FDA meeting this quarter and 48-week IMPACT data before year-end for pemvidutide in MASH."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-117144","json":"https://secwatch.observer/filing/0001104659-25-117144.json","markdown":"https://secwatch.observer/filing/0001104659-25-117144.md","text":"https://secwatch.observer/filing/0001104659-25-117144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/0001104659-25-117144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925117144/tm2532420d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T15:51:39.410351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}